Navigation Links
SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Date:5/4/2009

CALGARY, May 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced that it has reached an agreement with AVAC Ltd. for a $1.5 million loan for the development of its Apo AIMilano candidate. AVAC is a private, not-for-profit company that invests in research initiatives and early stage commercial businesses that expand Alberta's value-added industry.

The funds will be advanced with an upfront payment followed by two smaller installments based on the execution of short term Apo AIMilano development milestones expected to be completed by January 2010. The funds are repayable at the end of 18 months with interest.

"This funding comes at a very important time as it will contribute towards the achievement of near-term objectives for our Apo AIMilano candidate and allow us to leverage additional funding opportunities," said James Szarko, President and CEO of SemBioSys Genetics Inc. "AVAC's continued support reflects the shared vision of our enabling technology platform and its applicability to biopharmaceuticals like Apo AIMilano. This next-generation drug has the potential to meet a very large unmet need in cardiovascular disease. The terms of the funding provide us sufficient time to execute substantial value-generating milestones for this promising program."

"AVAC has very high hopes for SemBioSys' technology platform and has been a strong supporter of the Company since 2001. The Apo AIMilano product has true blockbuster potential and will provide the medical community with new tools to address the debilitating and potentially life-threatening consequences of atherosclerosis," says Jim Hardin, AVAC Investment Manager.

"In addition to its direct investments in early-stage companies, AVAC also participates in commercially-relevant agricultural research and we are the leading early-stage venture capital fund-of-fund investor in Alber
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys provides update on insulin program
2. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
3. SemBioSys announces senior management changes
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. SemBioSys begins phase I/II trial of insulin produced in plant seeds
6. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
7. SemBioSys announces second quarter 2008 financial and operational results
8. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
9. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
10. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
11. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... Favrille, Inc. (Nasdaq:,FVRL) today announced that it ... 2008 indicating that, for the last 30 consecutive ... common stock has been below,the minimum $1.00 per ... $5,000,000 minimum market value of publicly held shares ...
... the ... Treatment of Stuttering, ROANOKE, Va., ... non-profit research and,clinical center ( http://www.stuttering.org ) specializing ... stuttering,therapy with advanced behavioral, electronic and computer technologies that,significantly improve ...
... for Aging Services Technologies, (CAST) to Expedite Emerging ... 15 Samarion CEO Mark Rodgers was,recently named ... to help lead the charge to expedite emerging ... an international coalition ensuring that technology solutions,attain their ...
Cached Biology Technology:Favrille Announces Receipt of Nasdaq Letters 2Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech 2Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech 3Samarion CEO Mark Rodgers Named CAST Commissioner 2
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... in Genome Research on Nov. 4, scientists at ... previously believed to be "junk" DNA is one of the ... 50 percent of human DNA has been referred to as ... A major source of these repeats is internal viruses that ...
... hormone produced by fat and other tissues into mice, researchers ... significantly lowered blood sugar levels in normal and obese mice. ... be a promising target for managing insulin resistance and type ... insulin are insufficient to lower blood sugar (glucose) levels, is ...
... the near future it will be possible to customise ... the genetic profile of the individual. Dutch researcher Amber ... ready for this so-called nutrigenomics. Ronteltap concludes that many ... become a reality. Nutrigenomics is a discipline ...
Cached Biology News:'Junk' DNA proves functional 2'Junk' DNA proves functional 3Apelin hormone injections powerfully lower blood sugar 2Consumer not ready for tailor-made nutrition 2
Fast, sensitive quantitation of total MEK 1/2 concentration....
Argon Calibration Source...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
Biology Products: